Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 6/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.49 |
| ▸ | FEN1 | P39748 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5912674 | 0.85 | ERCC5 (0.57) | CYP19A1ALDH1A1LMNAMAPK1SMN1; SMN2 | |
| SCHEMBL18839642 | 0.83 | MAPK1 (0.50) | CYP19A1ALDH1A1LMNAMAPK1SMN1; SMN2 | |
| SCHEMBL18839820 | 0.82 | PDE4A (0.53) | ALDH1A1LMNASMN1; SMN2RAB9AMEN1 | |
| SCHEMBL10959104 | 0.82 | ALDH1A1 (0.47) | CYP19A1ALDH1A1LMNAMAPK1SMN1; SMN2 | |
| SCHEMBL6577327 | 0.81 | HPGD (0.54) | ALDH1A1LMNAMAPK1ERCC5FEN1 | |
| SCHEMBL8531345 | 0.80 | POLB (0.47) | CYP19A1ALDH1A1LMNAMAPK1SMN1; SMN2 | |
| SCHEMBL11271744 | 0.79 | HPGD (0.53) | ALDH1A1LMNAMAPK1ERCC5FEN1 | |
| SCHEMBL11069413 | 0.79 | ALDH1A1 (0.52) | ALDH1A1LMNAMAPK1ERCC5FEN1 | |
| SCHEMBL18839756 | 0.79 | MMP9 (0.44) | CYP19A1ALDH1A1LMNASMN1; SMN2NPC1 | |
| SCHEMBL10961137 | 0.78 | SLC5A1 (0.44) | ALDH1A1MAPK1SMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4316037-A | N-Benzyl and N-substituted benzyl tetrazole-5-carboxylic acids and the preparation thereof | AMERICAN HOME PRODUCTS CORPORATION (US) | 1982-02-16 | — | — | US | claimed |
| EP-3508484-B1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-04-07 | — | — | EP | disclosed |
| CN-108774214-B | Heterocyclic amides as kinase inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2021-03-09 | — | — | CN | disclosed |
| US-10940154-B2 | Heterocyclic amides as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-03-09 | — | — | US | disclosed |
| US-10940154-B2 | Heterocyclic amides as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-03-09 | — | — | US | disclosed |
| US-10933070-B2 | Heterocyclic amides as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-03-02 | — | — | US | disclosed |
| US-10933070-B2 | Heterocyclic amides as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-03-02 | — | — | US | disclosed |
| EP-3342771-B1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-11-25 | — | — | EP | disclosed |
| EP-3375780-B1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-06-03 | — | — | EP | disclosed |
| CN-106928203-B | Heterocyclic amides as kinase inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2020-02-07 | — | — | CN | disclosed |
| US-20100174091-A1 | Process for the preparation of tetrazolytetrahydrocyclopentapyrazoles | MERCK SHARP & DOHME LTD. (GB) | 2010-07-08 | — | — | US | disclosed |
| US-7692038-B2 | Crystalline forms | PFIZER, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-4442115-A | ANTI-ASTHMA | MAY & BAKER LIMITED (GB) | 1984-04-10 | — | — | US | disclosed |
| US-4316037-A | N-Benzyl and N-substituted benzyl tetrazole-5-carboxylic acids and the preparation thereof | AMERICAN HOME PRODUCTS CORPORATION (US) | 1982-02-16 | — | — | US | disclosed |
| US-4129735-A | MULTISTAGE FROM AN OXAMIC ACID ESTER AND PHOSPHORUS PENTACHLORIDE | AMERICAN HOME PRODUCTS CORPORATION (US) | 1978-12-12 | — | — | US | disclosed |
| US-4123432-A | ANTIALLERGENS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1978-10-31 | — | — | US | disclosed |
| US-4116960-A | ANTI-ALLERGIC | AMERICAN HOME PRODUCTS CORPORATION (US) | 1978-09-26 | — | — | US | disclosed |
| US-4057632-A | ANTIBODY-ANTIGEN INHIBITORS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1977-11-08 | — | — | US | disclosed |
| US-4044144-A | ANTIALLERGY | AMERICAN HOME PRODUCTS CORPORATION (US) | 1977-08-23 | — | — | US | disclosed |
| US-4013647-A | ANTIALLERGENS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1977-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10940154-B2 | Heterocyclic amides as kinase inhibitors | CNKSR1, ARAF, MAP4K2 | CYP19A1 1264/4885ALDH1A1 2245/4885LMNA 2145/4885 |
| US-20100174091-A1 | Process for the preparation of tetrazolytetrahydrocyclopentapyrazoles | CYP2F1, CYP3A7, DHFR | CYP19A1 585/4885ALDH1A1 407/4885LMNA 2374/4885 |
| US-10933070-B2 | Heterocyclic amides as kinase inhibitors | CNKSR1, ARAF, MAP4K2 | CYP19A1 1264/4885ALDH1A1 2245/4885LMNA 2145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.